Head-to-head · free

Teva Pharmaceutical Industries Limited vs 10x Genomics, Inc.

TEVA vs TXG — return on capital, cash generation, margins and balance sheet side by side.

TEVA

5 / 7

measures where TEVA leads

TXG

2 / 7

measures where TXG leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureTEVA · FY2025TXG · FY2025
Revenue$1.5B$642.8M
Net income$1.4B(43.5M)
Revenue growth (yearly, multi-year)-44.6%7.0%
Free cash flow—$130.1M
Free cash flow margin—20.2%
Net cash / (debt)——
ROIC——
Return on equity21.2%-5.8%
Gross margin51.8%69.1%
Operating margin22.9%-17.2%
Net debt / EBITDA4.19x27.61x

Figures are as reported by each company; latest fiscal year shown.

Where Teva Pharmaceutical Industries Limited's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TEVA profile →

Where 10x Genomics, Inc.'s cash went (FY2025)

Capital spending
$5.9M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TXG profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons